Insmed CEO Lewis sells $1.99 million in stock

William Lewis (JO:LEWJ), the Chair and CEO of Insmed Inc (NASDAQ:INSM), executed a series of stock transactions on March 3, 2025, according to a recent SEC filing. Lewis sold shares amounting to a total value of approximately $1.99 million, with sale prices ranging from $76.23 to $80.90 per share. The transactions come as the company’s stock has delivered an impressive 178.76% return over the past year, according to InvestingPro data.

The transactions were conducted under a 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks at a later date. Following these sales, Lewis holds 334,186 shares directly.

In addition to the sales, Lewis also exercised stock options, acquiring 18,750 shares at prices between $10.85 and $22.76. These option exercises totaled approximately $500,855. The shares acquired through options were not part of the sales transactions.

The filing also mentions indirect transactions through the Katie Procter Dynasty Trust, which saw additional sales of shares. The trust sold shares at prices within the same range, further contributing to the overall transaction activity on that date.

Insmed Inc, based in Bridgewater, NJ, is a company operating in the pharmaceutical preparations industry. The company, currently valued at $14.03 billion, maintains strong liquidity with a current ratio of 5.45, though it remains unprofitable with earnings per share of -$5.57 over the last twelve months.

In other recent news, Insmed Incorporated announced its fourth-quarter 2024 financial results, revealing a larger-than-expected loss per share but revenue that surpassed forecasts. The company reported an earnings per share (EPS) of -1.32, missing the anticipated -1.18, while revenue reached $104.44 million, exceeding the forecasted $97.68 million. UBS analyst Trung Huynh responded by raising the price target for Insmed to $105, maintaining a Buy rating, following the company’s earnings call and corporate updates. Additionally, RBC Capital initiated coverage on Insmed with an Outperform rating and a $100 price target, highlighting the potential of Insmed’s drug brensocatib, which is expected to launch in 2025.

The U.S. Food and Drug Administration (FDA) has set a target action date of August 12, 2025, for Insmed’s brensocatib, a treatment for non-cystic fibrosis bronchiectasis, under the Prescription Drug User Fee Act (PDUFA). The NDA for brensocatib was granted Priority Review status, based on the outcomes of the Phase 3 ASPEN study. The FDA has not requested an advisory committee meeting, suggesting a straightforward regulatory review process. Insmed’s Chief Medical (TASE:BLWV) Officer, Dr. Martina Flammer, expressed satisfaction with the FDA’s ongoing communication and the company’s commitment to completing the review process.

Investors are keeping a close eye on Insmed’s strategic focus on expanding its sales force and preparing for new product launches, which have positioned the company well in the competitive biotech landscape. Insmed reported a robust 19% year-over-year growth in global net revenue for 2024, driven by significant contributions from the U.S. and Japan. The company’s pipeline developments, including the potential FDA approval of brensocatib and anticipated clinical data readouts, are expected to serve as significant milestones that could drive the company’s growth trajectory in 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.